The 2023 Belgian clinical guidance on anticoagulation management in hospitalized and ambulatory COVID-19 patients

Thomas Vanassche, Matthias M Engelen, Christelle Orlando, Kristel Vandenbosch, Alain Gadisseur, Cedric Hermans, Kristin Jochmans, Jean-Marc Minon, Serge Motte, Harlinde Peperstraete, Pierre Péters, Muriel Sprynger, Patrizio Lancellotti, Isabelle Dehaene, Patrick Emonts, Christophe Vandenbriele, Peter Verhamme, Cecile Oury

Research output: Contribution to journalArticlepeer-review

Abstract

COVID-19 is associated with an increased risk for thrombotic complications. The trials investigating the optimal thromboprophylactic dose are performed in challenging times and seemingly produce conflicting evidence. The burdensome circumstances, divergent endpoints, and different analytical approaches hamper comparison and extrapolation of available evidence. Most importantly, clinicians should provide thromboprophylaxis in hospitalized COVID-19 patients while (re)assessing bleeding and thrombotic risk frequently. The COVID-19 Thromboprophylaxis Working Group of the BSTH updated its guidance document. It aims to summarize the available evidence critically and to guide clinicians in providing the best possible thromboprophylaxis.

Original languageEnglish
Pages (from-to)497-508
Number of pages12
JournalActa Clinica Belgica
Volume78
Issue number6
Early online date7 Aug 2023
DOIs
Publication statusPublished - Dec 2023

Bibliographical note

Publisher Copyright:
© Belgian Society of Internal Medicine and Royal Belgian Society of Laboratory Medicine (2023).

Keywords

  • COVID-19
  • Practice guideline
  • Anticoagulants
  • thrombosis

Fingerprint

Dive into the research topics of 'The 2023 Belgian clinical guidance on anticoagulation management in hospitalized and ambulatory COVID-19 patients'. Together they form a unique fingerprint.

Cite this